Just Hit Highest Amazon Sales Rank Recorded, page-8

Immuron made it clear in an October 2018 filing that, with respect to the liver disease trials, the plan is to partner IMM-124E for all three indications (NASH, ASH, P. NAFLD).  ASH results next quarter, P. NAFLD this year.  So yes, that deal likely won't come until all the results are in.  Regardless, Immuron isn't paying a dime for the ASH trial (which is essentially completed at this point) or the P. NAFLD trial.  At this point, all we are paying for is the C.DIFF. trial.

We burned $500k from July 1, 2018 until December 31, 2018.  We have $4,200,000 in the bank, with growing Travelan sales.  By any measure, U.S. Travelan sales should start to take off, and turn the company profitable.  By any forecast, Immuron has enough cash by far to complete all the Phase 2 liver disease trials and get a partnership done.  And if anyone bites, forget about it.  With our ultra low share count, there's is gigantic upside here.  Leewnhoeck believes the shares are worth $1.92 AUD, which at this point is a 10X upside just about.  

https://www.immuron.com.au/assets/files/IMC-Leewnhoeck-Report-on-Immuron-13-Feb-2017.pdf